BioMarin Pharmaceutical Inc., commonly known by its ticker symbol BMRN, is a leading biotechnology company specializing in the development and commercialization of therapies for various rare genetic diseases. The company has its headquarters in San Rafael, California, and operates globally with a market presence in over 50 countries. BioMarin Pharmaceutical Inc., founded in 1996, is listed on the NASDAQ stock exchange and has been making significant strides in its field since its inception.
The company’s portfolio is primarily focused on providing innovative biopharmaceuticals for patients who often have few or no treatment options. These pharmaceuticals target a diversity of rare genetic diseases, including PKU, a metabolic disorder; hemophilia, a blood disorder; and achondroplasia, a bone-growth disorder among others.
BioMarin’s approach is based on pioneering first-to-market products. These include Palynziq and Kuvan for PKU, Naglazyme for MPS VI, a progressive, debilitating and life-threatening disease, and Vimizim for Morquio Syndrome, an inherited disorder of metabolism. They also have Brineura in their portfolio, the first and only treatment for CLN2 disease, a type of Batten disease. Each of these therapies had no approved treatment options prior to BioMarin's therapeutic applications.
In recent years, BioMarin has been working on innovative gene therapy approaches, most notably for hemophilia A. It is also looking into therapies for other deficiencies and disorders with its robust and diverse pipeline.
The company has built a reputation for developing novel drugs that address areas of high unmet medical need and obtaining approval for these drugs in global markets. It’s worth mentioning that BioMarin also invests heavily in research and development. The company employs a team of over 2,400 employees, including many leading scientists and researchers devoted to the discovery and advancement of novel therapeutics.
In conclusion, BioMarin Pharmaceutical Inc. stands out as a committed entity in the development and production of treatments for rare genetic disorders. Its innovative therapies have brought significant relief to patients worldwide and its consistent focus on research and development positions it aptly for continued advances in the biopharmaceutical industry. The company’s commitment to improving lives and its unwavering dedication to scientific innovation aptly justify its reputation as a leader in the biotech industry.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
BioMarin Pharmaceutical has decided to discontinue the development of Voxzogo (vosoritide) for Noonan syndrome, citing study feasibility and the current treatment landscape, not safety or efficacy concerns. This follows an earlier halt in development for other short stature indications due to an adverse event. Despite this discontinuation, Voxzogo, a key revenue driver for BioMarin, continues to pursue label expansion for hypochondroplasia and idiopathic short stature, while also navigating increasing competition from rivals like Ascendis Pharma and BridgeBio Pharma.
BioMarin Pharmaceutical Inc. has appointed Robert Plenge, M.D., Ph.D., Chief Research Officer and Head of Research at Bristol Myers Squibb, to its Board of Directors, effective September 10, 2026. Dr. Plenge brings extensive experience in human genetics, drug discovery, and the pharmaceutical industry. His appointment is expected to provide valuable scientific perspective as BioMarin develops its research capabilities and expands its pipeline for genetic conditions.
BioMarin Pharmaceutical Inc. (BMRN) saw its shares jump 5% following a global patent settlement with Ascendis Pharma A/S (ASND) over Ascendis's achondroplasia drug Yuviwel. The agreement resolves ongoing litigation across multiple jurisdictions and includes a royalty payment structure where BioMarin will receive 20% of Yuviwel's net sales in the US and 18% in the EU, Brazil, and South Korea until May 2030, in exchange for a non-exclusive license. This settlement provides BioMarin with a consistent revenue stream and removes litigation uncertainty for Ascendis, allowing unrestricted commercialization of Yuviwel.
This article analyzes Biomarin Pharmaceutical Inc. (NASDAQ: BMRN) using algorithmic entry frameworks. It identifies weak near-term sentiment and a mid-channel oscillation pattern, suggesting a significant risk-reward short setup. The analysis provides three distinct trading strategies (Position Trading, Momentum Breakout, and Risk Hedging) tailored to different risk profiles, alongside multi-timeframe signal analysis.
BioMarin Pharmaceutical Inc. announced positive results from its Phase 3 CANOPY-HCH-3 study of VOXZOGO (vosoritide) in children with hypochondroplasia, which were published in NEJM Evidence and presented at the ESPE 2026 Annual Meeting. The study demonstrated statistically significant improvements in growth measures like annualized growth velocity, standing height, height Z-score, and arm span. BioMarin has submitted these data to the FDA for a supplemental New Drug Application to expand VOXZOGO's treatment indication to include children with hypochondroplasia.